2019
DOI: 10.4103/jcrt.jcrt_273_17
|View full text |Cite
|
Sign up to set email alerts
|

A comprehensive review of surgical margin in oral squamous cell carcinoma highlighting the significance of tumor-free surgical margins

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
32
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
7
3

Relationship

0
10

Authors

Journals

citations
Cited by 36 publications
(33 citation statements)
references
References 31 publications
1
32
0
Order By: Relevance
“…For resectable tumors, surgery is superior to all other therapies, but for surgical resection, sufficient margins for the primary tumor must be available. Failure to obtain a clear surgical margin leads to an increased risk of local recurrence and subsequently a poor prognosis [127].…”
Section: Surgical Resectionmentioning
confidence: 99%
“…For resectable tumors, surgery is superior to all other therapies, but for surgical resection, sufficient margins for the primary tumor must be available. Failure to obtain a clear surgical margin leads to an increased risk of local recurrence and subsequently a poor prognosis [127].…”
Section: Surgical Resectionmentioning
confidence: 99%
“…Surgery remains the primary treatment option for most solid malignant tumors [1]. Precise and complete resection of the whole tumor without unnecessary removal of the neighboring healthy tissue is a prerequisite for a successful outcome [2]. Unfortunately, visual distinction between the malignant and healthy tissue using only the surgeon's naked eye is often almost impossible.…”
Section: Introductionmentioning
confidence: 99%
“…About 300,000 new cases are estimated to be diagnosed annually worldwide, and locoregional recurrences may occur in 30-35% of patients, 20% of whom die of OSCC eventually [3,4]. The high recurrence and metastasis rate of OSCC lead to the 5-year survival rate of less than 50% [5,6]. In recent years, treatment options, particularly for advanced (III and IV) malignancies, have been surgery, radiation and/or chemotherapy and targeted therapy, including cisplatin (CDDP), docetaxel (DTX), 5-Fluorouracil (5-FU) and cetuximab [1,7].…”
Section: Introductionmentioning
confidence: 99%